Colorado Adopts First State Payment Cap for Amgen’s Enbrel (1)

Amgen Inc.‘s blockbuster biologic Enbrel will be the first product to face a state-imposed health plan payment cap under a landmark vote by a key Colorado affordability panel Friday.

Four members of the Colorado Prescription Drug Affordability Board voted to finalize an amended version of their proposal to cap what health plans in the state pay for Enbrel at $600 per 50 mg/ml unit, based on the current maximum fair price for the autoimmune treatment that’s set to go into effect in the federal Medicare program in January 2026. One of the board’s five members, Sami Diab, has recused ...